# Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer

> **NCT00003733** · PHASE2 · UNKNOWN · sponsor: **SmithKline Beecham** · enrollment: 40 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** paclitaxel
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00003733
- **Lead sponsor:** SmithKline Beecham
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003733, "Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00003733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*